
Medtronic plans US$380M Contego Medical acquisition for vascular portfolio
The proposed purchase adds carotid and clot-removal devices, with possible later payments and closing expected in Medtronic's fiscal third quarter.

FTSE Russell's next list update is Nov. 20, with membership changes scheduled to take effect after the Dec. 11 market close.

The proposed purchase adds carotid and clot-removal devices, with possible later payments and closing expected in Medtronic's fiscal third quarter.

The explorer omitted ownership stakes, acquisition price and placement terms, with technical reporting targeted for year-end.
A fixed 7 per cent coupon replaces the floating rate, while holders can demand repayment in 2029 or convert at an initial US$6.51 per share.
The kidney-drug developer expects its cash and securities to last beyond 2027, including spending for a potential OLC launch.

Faeth will sponsor the Phase 1b/2 study and retain PIKTOR rights, while Roche supplies giredestrant under the collaboration.

The share-funded acquisition carries a 2 per cent royalty, while six of the eight Vancouver Island claims remain under application.

Five surface chip samples from Selkirk's Downie Gold property add northern results, but true thickness and continuous grades remain unproven.

The Swedish company reports 3,506 bitcoin and zero-interest convertible debt, but discloses no new credit commitment or collateral terms.
The listed property vehicle plans a 75.1 per cent interest in two campuses, with a 7 per cent initial capitalization rate.
Trading continues on Nasdaq and the TSX as the cannabis producer faces a consecutive-day bid-price test to regain compliance.
The balance excludes customer deposits, and the weekly post discloses no sale proceeds or average execution price.
The Financial Times identifies Amazon as the customer, while Fermi says a definitive long-term lease remains under negotiation.
The applications follow a Phase 3 trial showing 27 per cent fewer painful crises versus placebo, with regulatory action expected in 2027.
A one-time gain is expected to exceed fourth-quarter operating expenses, while full-year guidance still calls for a loss.
Convertible-note principal stood at US$486.5 million, with about 16,116 bitcoin pledged as the company evaluates operating businesses.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The proceeds lift treasury above C$24 million as the developer targets a late January feasibility study for Murray Brook and Caribou.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The agency found the progression-free survival benefit insufficient without statistically significant overall survival gains.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The tally includes buildings, power systems and planned investment, while NVIDIA's revenue outlook excludes China data centre compute sales.
The company held C$2.356 million in cash at Sept. 30 and is negotiating a non-binding proposal to acquire a controlling stake in a Polish drone business.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
The explorer will reassess working capital needs and financing alternatives after dropping its October offering.

The Grand Est site will recover cobalt, nickel and copper from black mass, but Veolia disclosed no investment cost or earnings forecast.

Uranium sales costs averaged US$87.22 per pound, while the producer awaits Texas approvals for extraction targets before year-end.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
International medical sales supplied 59 per cent of quarterly revenue, while gross margin and adjusted EBITDA declined sequentially.

Canada and Germany have completed competition reviews, Curaleaf says, while its offer remains outstanding until Dec. 4.

The board accepted its committee's recommendation on Oct. 26, citing the harvest, a stronger outlook and debt repayment.

The submission draws on studies involving more than 1,000 participants, with a first-half 2027 launch still subject to FDA approval.